Show simple item record

dc.contributor.authorAmal, Andi Sri Suriati
dc.contributor.authorHussain, Samsinah
dc.contributor.authorJalaluddin, Mohd. Amin
dc.identifier.citation[1]. Ali, MS, Chaudhary, MS, & Takieddin, MA 1999, ‘Simultaneous determination of metronidazole benzoate, methylparaben and propylparaben by high-performance liquid chromatography’, Drug Development on Industrial Pharmacy, vol.25, No. 10, pp. 1143-1147. [2]. Aulton, ME 1988, Pharmaceutics: the Science of Dosage Form Design, ELBS, Churchill Livingstone, United Kingdom. [3]. Allal, AS, Dulquerov, P, & Bieri, S 2000, ‘Assessment of quality of life in patients treated with accelerated radiotherapy for laryngeal and hypopharyngeal carcinomas’, Head Neck, vol22, pp. 288-293. [4]. Alpöz, E, Guneri, P, Onder, G, Cankaya, H, Kabasakal, Y, & Kose, T 2008, ‘The Efficacy of Xialine® in patients with Sjogren’s syndrome: a single-blind, cross-over study’, Clin Oral Invest, vol.12, pp. 165-172. [5]. British National Formulary 2009, British National Formulary. London. BMJ Group & RPS Publishing. [6]. Bolton, S 1997, Pharmaceutical Statistics Practical and Clinical Applications, Marcel Dekker Inc., New York. [7]. Burket, LW, Greenberg, MS, Glick, M, & Ship, JA 2008, Burket’s Oral Medicine, BC Decker Inc., Ontario. [8]. Davies, A & Finlay, IG 2005, Oral care in advanced disease. Oxford University Press London. [9]. Duxbury, AJ, Thakker, NS & Wastell, D G 1989, ‘A double-blind cross-over trial of a mucin-containing artificial saliva’, British Dental Journal, vol. 166, pp. 115-120. [10]. Fox, PC 1997, ‘Management of dry mouth’, Dental Clinics of North America,vol.41, no. 4, pp.863-875. [11]. Grotz, KA 2003, ‘Dental care for patients with antineoplastic radiotherapy of the head and neck’, Strahlenther Onkol, vol.179, pp. 275-278. [12]. Hatton, MN, Levine, MJ, Margarone, JE, & Aguirre, A 1987, ‘Lubrication and viscosity features of human saliva and commercially available saliva substitutes’, Journal Oral Maxillofac Surg, vol.45, pp. 496-499. [13]. Hahnel, S, Behr, M, Handel, G & Bürgers, R 2009, ‘Saliva substitutes for the treatment ofradiation-induced xerostomia-a review’, Support Care Cancer, vol.17, pp. 1331-1343. [14]. Joyston-Bechal, S & Kidd, EAM 1987, ‘The effect of three commercially available saliva substitutes on enamel in vitro’,Br. Dent. J,vol.63, pp. 187. [15]. Kelly, C 2001, ‘Sjogren’s syndrome and the respiratory system’, viewed 12 September 2002, <http://www. /WbHealth_A-Z of Health/About Sjogren_s Syndrome>. [16]. Lund, W, (ed) 1994, The Pharmaceutical Codex, 12th edn. The Pharmaceutical Press, London. [17]. Levine, MJ 1993, ‘Development of artificial salivas’, Critical Reviews in Oral Biology and Medicine, vol.4, no. 3-4, pp.279-286. [18]. Leung, VWH & Darvell, BW 1997, ‘Artificial salivas for in vitro studies of dental materials’, Journal of dentistry, vol.25, no. 6, pp. 475-484. [19]. Myers, EN & Ferris, RL 2007, Salivary Gland Disoreders, Springer, New York. [20]. Momm, F, Muller, M, & Tsekos, A 2001, ‘Xerostomia after radiotherapy: more effective treatment by a mucin-containing spray, HNO,vol.49, pp. 831-836. [21]. Momm, F, Volegova-Neher, NJ, Schulte-Monting, J & Guttenberger, R 2005, ‘Different Saliva Substitutes for Treatment of Xerostomia Following Radiotherapy’, Stralenther Onkol,vol. 181, pp. 231-236. [22]. Philip, DDS 1997, ‘Management of dry mouth’, Dental Clinic of North America, vol. 41, no. 4, pp. 863 –875. [23]. Ramachandran, S, Chen, S & Etzler F 1999, ‘Rheological characterization of hydroxypropylcellulose gels’, Drug Development and Industrial Pharmacy,vol. 25, no. 2, pp. 153-161. [24]. Radus, TP & Gretchen, G 1983, ‘Determination of antimicrobial preservatives in pharmaceutical formulations using reverse-phase liquid chromatography’ Journal of pharmaceutical sciences, vol. 72, no. 3, pp. 221-224. [25]. Regelink, G, Vissink, A, Reitsema, H & Nauta, JM 1998, ‘Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia’, Quintessense International,vol. 29 no. 6, pp. 383-387. [26]. Sidney, HW & James, RS 1993, Good Manufacturing Practices for Pharmaceuticals. Marcel Dekker, Inc., New York. [27]. Smith, ME, & Morton, DG 2001, The Digestive System, Elsevier Health Sciences. [28]. Srivastava, LM 2004, Textbook of Biochemistry and Human Biology, Prentice-Hall of India Private Limited, New Delhi. [29]. Sweetman SC (edt.) 2007, Martindale, The Extra Pharmacopeia, Pharmaceutical Press, Council of the Royal Pharmaceutical Society of Great Britain. [30]. The United States Pharmacopeial convention 1995, The United States Pharmacopeia. The National Formulary, The United States Pharmacopeial Convention, Inc., Reckville. [31]. Tenevuo, JO 1981, Human Saliva: Clinical Chemistry and Microbiolog, CRC Press. [32]. Troy, DB (ed) 2006, Remington: The Science and Practice of Pharmacy, Lippincot William & Wilkins, Philadelphia. [33]. Vissink, A, ‘s-Gravenmade, EJ, Panders, AK, Vermey, A, Petersen, JK, Visch, LL & Schaub, RMH 1983, ‘A clinical comparison between commercially available mucin- and CMC- containing saliva substitutes’, Int. J. Oral Surg, vol. 12, pp. 232-238. [34]. Vissink, A, Waterman, HA, ‘s-Gravenmade, EJ, Panders, AK. and Vermey, A 1984, ‘Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide’, Journal of Oral Pathology, vol. 13, pp. 22-28.in_ID
dc.description.abstractDry mouth or throat (xerostomia) is a clinical condition characterized by desiccation of the intraoral tissues. Patients with chronic or temporary sensation of dry mouth need some kind of treatment to relieve the symptoms. Causes of dry mouth include medications, autoimmune disease (Sjogren’s syndrome), radiotherapy or chemotherapy for cancer, hormone disorders and infections. The project is important not only because saliva substitutes are not manufactured locally, but also because most saliva substitutes use mucin (porcin in origin). Therefore there is a need to produce one with other source which has properties to mucin itself. The objective of this project is to produce saliva substitutes that can serve as mouth and throat lubricants. The first step was pre-formulation studies that involved characterization of active ingredients (physical, chemical, and mechanical properties) in order to choose what other ingredients (excipients) should be used in the preparation. Formulation studies also considered such factors as solubility, viscosity, and pH. The last step was assessment of safety and stability of the final product. The new artificial saliva formulations containing various ratios of SCMC (Sodium carboxymethyl cellulose), MC (methyl cellulose) and HPMC (hydroxypropyl methycellulose) have been developed. Combination of cellulose derivatives and albumin in these formulations resulted in the physical properties of these new artificial saliva substitutes closely resembling human saliva and mucin-based saliva substitutes. Formula we choose were the most suitable formulae due to their viscosity and pH properties which closely resemble human saliva and mucin based saliva substitutes.in_ID
dc.publisherUniversitas Muhammadiyah Surakartain_ID
dc.subjectArtificial Salivain_ID
dc.subjectSaliva Substitutein_ID
dc.subjectMouth and Throat Lubricantin_ID
dc.subjectMouth and Throat Moisturizerin_ID
dc.titlePreparation of Artificial Saliva Formulationin_ID

Files in this item


This item appears in the following Collection(s)

    Current Breakthrough in Pharmacy Materials and Analyses

Show simple item record